17 related articles for article (PubMed ID: 38748981)
1. Trastuzumab deruxtecan in breast cancer.
Martín M; Pandiella A; Vargas-Castrillón E; Díaz-Rodríguez E; Iglesias-Hernangómez T; Martínez Cano C; Fernández-Cuesta I; Winkow E; Perelló MF
Crit Rev Oncol Hematol; 2024 Jun; 198():104355. PubMed ID: 38621469
[TBL] [Abstract][Full Text] [Related]
2. Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2-expressing salivary gland carcinoma: a pooled analysis of two phase I studies.
Takahashi S; Bando H; Kinoshita I; Modi S; Tsurutani J; Bang YJ; Sato Y; Nakatani S; Lee C; Sugihara M; Okuda Y; Iwata H
Jpn J Clin Oncol; 2024 Apr; 54(4):434-443. PubMed ID: 38231777
[TBL] [Abstract][Full Text] [Related]
3. Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer.
Curigliano G; Dent R; Earle H; Modi S; Tarantino P; Viale G; Tolaney SM
ESMO Open; 2024 Apr; 9(4):102989. PubMed ID: 38613914
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of sacituzumab govitecan and trastuzumab deruxtecan on stable and active brain metastases in metastatic breast cancer patients-a multicenter real-world analysis.
Dannehl D; Jakob D; Mergel F; Estler A; Engler T; Volmer L; Frevert ML; Matovina S; Englisch A; Tegeler CM; Rohner A; Seller A; Hahn M; Pfister K; Fink A; Popp I; Lorenz S; Tabatabai G; Juhasz-Böss I; Janni W; Brucker S; Taran FA; Hartkopf A; Schäffler H
ESMO Open; 2024 May; 9(5):102995. PubMed ID: 38636292
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC.
Odintsov I; Makarem M; Nishino M; Bachert SE; Zhang T; LoPiccolo J; Paweletz CP; Gokhale PC; Ivanova E; Saldanha A; Rudin CM; Lockwood WW; Ladanyi M; Somwar R; Jänne PA; Sholl LM
J Thorac Oncol; 2024 May; 19(5):732-748. PubMed ID: 38154514
[TBL] [Abstract][Full Text] [Related]
6. Clinical benefit of post-trastuzumab deruxtecan treatment in patients with HER 2-positive unresectable or metastatic breast cancer: A single-institution retrospective observational study.
Isogai A; Nozawa K; Nakakami A; Komaki R; Ozaki Y; Endo Y; Kataoka A; Kotani H; Yoshimura A; Hattori M; Sawaki M; Iwata H
Breast Cancer Res Treat; 2024 May; ():. PubMed ID: 38797792
[TBL] [Abstract][Full Text] [Related]
7. Elucidating molecular mechanisms and therapeutic synergy: irreversible HER2-TKI plus T-Dxd for enhanced anti-HER2 treatment of gastric cancer.
Liu J; Zhu T; Zhao R; Ren W; Zhao F; Liu J
Gastric Cancer; 2024 May; 27(3):495-505. PubMed ID: 38386239
[TBL] [Abstract][Full Text] [Related]
8. RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer.
Singh H; Sahgal P; Kapner K; Corsello SM; Gupta H; Gujrathi R; Li YY; Cherniack AD; El Alam R; Kerfoot J; Andrews E; Lee A; Nambiar C; Hannigan AM; Remland J; Brais L; Leahy ME; Rubinson DA; Schlechter BL; Meyerson M; Kuang Y; Paweletz CP; Lee JK; Quintanilha JCF; Aguirre AJ; Perez KJ; Huffman BM; Rossi H; Abrams TA; Kabraji S; Trusolino L; Bertotti A; Sicinska ET; Parikh AR; Wolpin BM; Schrock AB; Giannakis M; Ng K; Meyerhardt JA; Hornick JL; Sethi NS; Cleary JM
Clin Cancer Res; 2024 Apr; 30(8):1669-1684. PubMed ID: 38345769
[TBL] [Abstract][Full Text] [Related]
9. Molecular Landscape and Clinical Implication of CCNE1-amplified Esophagogastric Cancer.
Rustgi N; Wu S; Samec T; Walker P; Xiu J; Lou E; Goel S; Saeed A; Moy RH
Cancer Res Commun; 2024 Jun; 4(6):1399-1409. PubMed ID: 38717153
[TBL] [Abstract][Full Text] [Related]
10. Sustained Clinical Complete Response after Discontinuation of Trastuzumab-deruxetecan Due to Interstitial Pneumonia for HER2-positive Gastric adenocarcinoma with Enteroblastic Differentiation (GAED): A Case Report.
Suzuki N; Odawara N; Fujisawa G; Ishibashi R; Hata M; Oya Y; Tamada K; Hayashi T; Abe S; Miyakawa Y; Hayakawa Y; Shinozaki-Ushiku A; Ushiku T; Boku N; Fujishiro M
Intern Med; 2024 Jun; ():. PubMed ID: 38839335
[TBL] [Abstract][Full Text] [Related]
11. Frequency and Nature of Genomic Alterations in ERBB2-Altered Urothelial Bladder Cancer.
Leary JB; Enright T; Bakaloudi DR; Basnet A; Bratslavsky G; Jacob J; Spiess PE; Li R; Necchi A; Kamat AM; Pavlick DC; Danziger N; Huang RSP; Lin DI; Cheng L; Ross J; Talukder R; Grivas P
Target Oncol; 2024 May; 19(3):447-458. PubMed ID: 38570422
[TBL] [Abstract][Full Text] [Related]
12. State of the art and upcoming trends in HER2-directed therapies in gastrointestinal malignancies.
Lee J; Ku G
Curr Opin Oncol; 2024 Jul; 36(4):326-331. PubMed ID: 38726843
[TBL] [Abstract][Full Text] [Related]
13. The Molecular Landscape of Gastric Cancers for Novel Targeted Therapies from Real-World Genomic Profiling.
Yamamoto H; Arai H; Oikawa R; Umemoto K; Takeda H; Mizukami T; Kubota Y; Doi A; Horie Y; Ogura T; Izawa N; Moore JA; Sokol ES; Sunakawa Y
Target Oncol; 2024 May; 19(3):459-471. PubMed ID: 38613733
[TBL] [Abstract][Full Text] [Related]
14. Impact of Genomic Alterations on Efficacy of Trastuzumab Deruxtecan Against Human Epidermal Growth Factor Receptor-2-Positive Advanced Gastric Cancer.
Yamaguchi K; Ito M; Isobe T; Koreishi S; Taguchi R; Uehara K; Ueno S; Imajima T; Kitazono T; Tsuchihashi K; Ohmura H; Yoshihiro T; Tanoue K; Nishiyori S; Iwama E; Maeda T; Akashi K; Baba E
JCO Precis Oncol; 2024 May; 8():e2300681. PubMed ID: 38748981
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]